Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-Year results from the AIM trial

Annals of the Rheumatic Diseases

Volumn 70, Issue 10, 2011, Pages 1826-1830

  Kremer, Joel M ^a   Russell, Anthony S ^b   Emery, Paul ^c,d   Abud Mendoza, Carlos ^e   Szechinski, Jacek ^f   Westhovens, Rene ^g   Li, Tracy ^h   Zhou, Xianhuang ^h   Becker, Jean Claude ^h   Aranda, Richard ^h   Peterfy, Charles ⁱ   Genant, Harry K ^j  

^a ALBANY MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^e UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^f WROCLAW MEDICAL UNIVERSITY   (Poland)

^g Department of Rheumatology   (Belgium)

^h BRISTOL MYERS SQUIBB   (United States)

ⁱ Spire Sciences LLC   (United States)

^j SYNARC INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; METHOTREXATE; PLACEBO;

AMERICAN COLLEGE OF RHEUMATOLOGY CRITERIA; ARTICLE; AUTOIMMUNE DISEASE; BASAL CELL CARCINOMA; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; GENANT MODIFIED SHARP SCORE; HEALTH ASSESSMENT QUESTIONNAIRE; HEART DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION; JOINT RADIOGRAPHY; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OPEN STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PSORIASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SHORT FORM 36; SJOEGREN SYNDROME; SKIN CANCER; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; THYROID TUMOR; TUBERCULOSIS; VASCULITIS;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASMS; OPPORTUNISTIC INFECTIONS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 80052508096     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.139345     Document Type: Article

References (13)

1. Kremer J.M., Genant H.K., Moreland L.W., et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial. Ann Intern Med 2006;144:865-876 (Pubitemid 46768126)
2. Kremer J.M., Genant H.K., Moreland L.W., et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 2008;58:953-963 (Pubitemid 351563996)
3. Genant H.K., Peterfy C.G., Westhovens R., et al. Abatacept inhibits progression of structural damage in rheumatoid arthritis: Results from the long-term extension of the AIM trial. Ann Rheum Dis 2008;67:1084-1089
4. Westhovens R., Kremer J.M., Moreland L.W., et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: A 5-year extended phase IIB study. J Rheumatol 2009;36:736-742
5. Breedveld F.C., Weisman M.H., Kavanaugh A.F., et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37. (Pubitemid 43122183)
6. Klareskog L., Gaubitz M., Rodriguez-Valverde V., et al.; Etanercept Study 301 Investigators. A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs. Ann Rheum Dis 2006;65:1578-1584 (Pubitemid 44799668)
7. Van der Heijde D., Klareskog L., Rodriguez-Valverde V., et al.; TEMPO Study Investigators. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006;54:1063-1074 (Pubitemid 43672919)
8. Kremer J.M., Weinblatt M.E., Bankhurst A.D., et al. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: Continued observations. Arthritis Rheum 2003;48:1493-1499 (Pubitemid 36682355)
9. Schiff M., Keiserman M., Codding C., et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: A phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096-1103
10. Schiff M.H., Burmester G.R., Kent J.D., et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:889-894
11. Kremer K., Westhovens R., Luggen M., et al. Long-term efficacy and safety of Abatacept through 3 years of treatment in rheumatoid arthritis patients in the AIM and ATTAIN trials. Arthritis Rheum 2007;56(Suppl 9):S300, Abstract 699.
12. Simon T.A., Smitten A.L., Franklin J., et al. Malignancies in the rheumatoid arthritis abatacept clinical development programme: An epidemiological assessment. Ann Rheum Dis 2009;68:1819-1826
13. Buch M.H., Aletaha D., Emery P., et al. Reporting of long-term extension studies: Lack of consistency calls for consensus. Ann Rheum Dis 2011;70:886-890